NCT04652479View on ClinicalTrials.gov

Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia

PHASE2CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

June 21, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions

Acquired Hyperinsulinemic Hypoglycemia

Interventions

DRUG

Avexitide

Avexitide (exendin 9-39) is a competitive antagonist of GLP-1 at its receptor

Trial Locations (1)

94304

Clinical and Translational Research Unit, Palo Alto

Sponsors

Collaborators (1)

Eiger BioPharmaceuticals

All Listed Sponsors

collaborator

Eiger BioPharmaceuticals

INDUSTRY

lead

Dr. Tracey McLaughlin, MD

OTHER

NCT04652479 - Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia | Biotech Hunter | Biotech Hunter